Navigation Links
Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Date:7/17/2008

Highlights Include Clinical Trial Updates

BETHESDA, Md., July 18 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. (AIM: NWBS and NWBT; OTC Bulletin Board: NWBO), (the "Company or NWBT"), today announced that Dr. Alton L. Boynton, its President and Chief Executive Officer, will deliver a presentation updating the Company's progress in the development of dendritic vaccines for the treatment of cancer, at the "Next Generation Vaccines" conference. The conference will be held on 17 &18 July, at the Gaylord National Resort and Convention Center in National Harbor, Maryland, USA. Dr. Boynton is scheduled to present as part of the Advances in Cancer Vaccines session on July 18th @ 11:15 am EST.

Dr. Boynton will provide an update on NWBT's product candidates, including therapeutic cancer vaccines DCVax(R)-Brain for the treatment of Glioblastoma multiforme and DCVax(R)-Prostate for hormone-independent prostate cancer.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicity, on a cost-effective basis. The Company has two broad platform technologies: dendritic cell-based vaccines and therapeutic antibodies. The Company is currently conducting a large Phase II clinical trial in GBM, which is designed and powered to serve as a pivotal trial. The Company has also received clearance from the FDA for a large Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has started a Phase I/II trial with DCVax(R) directed to ovarian cancer. The Company's second technology platform, involving antibodies to CXCR4, is at the late pre-clinical development stage.

For further information, please visit the company web site at http://www.nwbio.com

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in the Phase II trial of DCVax(R)-Brain and complete the trial on a timely basis, risks related to meeting the clinical endpoints in the planned Phase II clinical trial of DCVax(R)-Brain, risks related to manufacturing, risks related to the Company's ability to initiate, and enroll patients in, the planned Phase III trial of DCVax(R)-Prostate and complete the trial on a timely basis, the uncertainty of the clinical trials process and whether DCVax(R)-Prostate or DCVax(R)-Brain will demonstrate safety and efficacy, and the timely performance of third parties. Additional information on these and other factors, which could affect the Company's results, is included in its Securities and Exchange Commission filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.


'/>"/>
SOURCE Northwest Biotherapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Northwestern chemist investigates lost reds in Homer painting
2. Nikon Instruments Opens New Imaging Center at Northwestern University
3. Northwest Secures US$4.0 Million in Debt Financing
4. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
6. Lonza Withdraws Majority of Claims in Patent Lawsuit Against Northwest Biotherapeutics
7. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
8. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
9. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
10. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
11. Protalix BioTherapeutics Sets Record Date for Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 26, 2017 , ... Spectral imaging ... face every day. This unique capability combines high resolution imaging with spectral ... to deliver unprecedented datasets for chemical analysis, quality control, and decision-making. , Snapshot ...
(Date:7/26/2017)... MN (PRWEB) , ... July 26, 2017 , ... ... of Us Research Program at the National Institutes of Health (NIH), will be ... Conference. This annual conference provides a platform for a multi-stakeholder discussion on the ...
(Date:7/26/2017)... , July 26, 2017  Nurse practitioners play a crucial ... findings of a Merck Manuals survey released today. ... conference, revealed that most (88 percent) believe they spend at ... and prescriptions. ... Merck Manuals survey of 210 nurse practitioners ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... Director of Strategic Planning. His extensive background in consulting, development and marketing ... encompasses marketing and differentiation consulting, business strategy development, new product marketing and ...
Breaking Biology Technology:
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/28/2017)... 28, 2017 The report "Video ... Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), and ... Global Forecast to 2022", published by MarketsandMarkets, the market ... is projected to reach USD 75.64 Billion by 2022, ... The base year considered for the study is 2016 ...
Breaking Biology News(10 mins):